For this, we evaluated whether the increased IL-1β levels were responsible for the exacerbated damage induced by the inhibition of either IL-6 or IL-10 action in liver grafts from DBDs, in the absence and presence of steatosis, respectively. The gene discussed is IL6; the disease is steatosis.